From Nasdaq: 2025-02-13 09:00:00

Shares of CVS Health Corporation (NYSE: CVS) surged over 15% after releasing its Q4 2024 earnings report, sparking investor interest in a potential turnaround. While revenue reached $97.71 billion, adjusted EPS fell to $1.19, and operating income decreased across segments, hinting at challenges within the Health Care Benefits division. CVS Health forecasts adjusted EPS of $5.75 to $6.00 for 2025, signaling a possible earnings rebound despite ongoing competitive and regulatory challenges. The company’s strategic initiatives and projected recovery are generating cautious optimism among investors, but sustained improvement, particularly in the insurance segment, will be crucial for long-term value creation.



Read more at Nasdaq:: CVS Health: Earnings Beat Ignites Stock Rally